Author:
Nguyen Nhan H.,Glassman Fiona Y.,Dingman Robert K.,Shenoy Gautam N.,Wohlfert Elizabeth A.,Kay Jason G.,Bankert Richard B.,Balu-Iyer Sathy V.
Abstract
AbstractThe safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeutic proteins prior to their initial use is critical as it is often difficult to reverse an established immune response. Here, we discuss a rational design and testing of a phosphatidylserine-containing nanoparticle platform for novel oral prophylactic reverse vaccination approach, i.e., pre-treatment of a therapeutic protein in the presence of nanoparticles to prevent immunogenicity of protein therapies.
Funder
National Institute of Health
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Krishna, M. & Nadler, S. G. Immunogenicity to biotherapeutics—the role of anti-drug immune complexes. Front. Immunol. 7, 21. https://doi.org/10.3389/fimmu.2016.00021 (2016).
2. Dingman, R. & Balu-Iyer, S. V. Immunogenicity of protein pharmaceuticals. J. Pharm. Sci. 108, 1637–1654. https://doi.org/10.1016/j.xphs.2018.12.014 (2019).
3. Hermeling, S., Crommelin, D. J., Schellekens, H. & Jiskoot, W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21, 897–903. https://doi.org/10.1023/b:pham.0000029275.41323.a6 (2004).
4. Lumizyme [Package Insert]. (Genzyme Corporation CM, 2011).
5. Myozyme [Package Insert]. (Genzyme Corporation CM, 2017).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献